Log in to search using one of your social media accounts:

 

More Than Okay to Reduce Sorafenib Dose for Liver Cancer More Than Okay to Reduce Sorafenib Dose for Liver Cancer
Initially reducing the dosage of the oral therapy did not compromise overall survival in hepatocellular carcinoma and had important benefits.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Is There a Standard for Surgical Therapy of HCC? Is There a Standard for Surgical Therapy of HCC?
This study compared different guidelines regarding indication for resection and transplantation in patients with hepatocellular carcinoma, with and without underlying cirrhosis. Is there a consensus?BMJ Open Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Hepatocellular carcinoma: Resection vs. transplantation
(Deutsches Aerzteblatt International) Liver transplantation is the gold standard for treating early hepatocellular cancers. Because of the lack of donors, this option is, however, available to a limited degree only. Curative liver resection is an alternative in this setting. Markus B. Schoenberg, Julian N. Bucher, and coauthors investigated whether liver resection can yield results that are comparable to those of liver transplantation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 8, 2017 Category: Cancer & Oncology Source Type: news

Telomere Length Prognostic in Hepatocellular Carcinoma
Shortened telomeres in tumor cells, CA - associated fibroblasts tied to reduced survival, upped recurrence (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 24, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pathology, Journal, Source Type: news

Sirtex swings to a loss after ‘ challenging ’ year
Shares in Australian cancer treatment developer Sirtex Medical (ASX:SRX) plunged more than 15% yesterday after the company posted a net loss of -A$26.9 million in 2016, compared to a profit of A$54 million the year before. Sirtex has faced a barrage of obstacles this year, including a number of clinical trials that failed to meet primary endpoints. The company’s full-year results were hit by a slowdown in sales growth of its SIR-Spheres Y-90 radioactive microspheres and by the costs linked to its restructuring efforts. In June, Sirtex said it planned to cut 15% of its workforce, estimating that it would sav...
Source: Mass Device - August 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Source Type: news

How Do Direct-Acting Antivirals for HCV Affect HCC Risk? How Do Direct-Acting Antivirals for HCV Affect HCC Risk?
The latest data on the controversial hepatitis C-hepatocellular carcinoma treatment link are examined.Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 15, 2017 Category: Consumer Health News Tags: Gastroenterology Commentary Source Type: news

Bayer ’s stivarga receives EU marketing approval for HCC treatment
The European Commission (EC) has granted marketing authorisation for Bayer ’s stivarga (regorafenib) used for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with nexavar (sorafenib). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 7, 2017 Category: Pharmaceuticals Source Type: news

Bayer Receives EU Approval for Stivarga ® (Regorafenib) for the Second-Line Systemic Treatment of Liver Cancer (for specialized target groups only)
Approval marks first treatment advance in nearly a decade and is based on data from the Phase III RESORCE study, in which Stivarga ® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) / Nexavar is the only approved first-line treatment and Stivarga the only approved second-line therapy in Europe and the United States fo r patients with HCC (Source: Bayer Company News)
Source: Bayer Company News - August 7, 2017 Category: Pharmaceuticals Source Type: news

Eisai seeks marketing authorisation for lenvatinib from EMA
Eisai has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for first-line use of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 27, 2017 Category: Pharmaceuticals Source Type: news

With HCV on the Run, Meet the New Challenge: HCC With HCV on the Run, Meet the New Challenge: HCC
Dr William Balistreri reviews several studies investigating the uptick in hepatocellular carcinoma.Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2017 Category: Consumer Health News Tags: Gastroenterology Commentary Source Type: news

Tiziana enrols first patient in Phase IIa trial of milciclib to treat HCC
UK-based biotechnology firm Tiziana Life Sciences has started patient enrolment in a Phase IIa clinical trial of milciclib for the treatment of hepatocellular carcinoma (HCC) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - July 19, 2017 Category: Pharmaceuticals Source Type: news

Hepatocellular Carcinoma and DAAs: A Never Ending Story? Hepatocellular Carcinoma and DAAs: A Never Ending Story?
In this commentary, the authors examine contributing factors which might be skewing the data concerning DAAs and hepatocellular carcinoma risk in certain subsets of treated patients.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 12, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Liver Cancer: Microwave Ablation and Ideal Surgical Margin Liver Cancer: Microwave Ablation and Ideal Surgical Margin
New findings in the treatment of hepatocellular carcinoma include results from a trial comparing microwave with radiofrequency ablation and a study of the ideal surgical margin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 5, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Sustained Response to Direct-acting HCV Antivirals Tied to Lower HCC Risk Sustained Response to Direct-acting HCV Antivirals Tied to Lower HCC Risk
A sustained virologic response to direct-acting antiviral treatment of hepatitis C (HCV) is associated with a “ considerable ” reduction in the risk of hepatocellular carcinoma (HCC), researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 3, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Incidence of Liver Cancer After DAA Treatment of Chronic HCV Incidence of Liver Cancer After DAA Treatment of Chronic HCV
Is there a relationship between DAA therapy for chronic HCV and increased risk of hepatocellular carcinoma? Data has been conflicting.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Bayer Receives Approval for Stivarga ® in Japan for Second-Line Treatment of Hepatocellular Carcinoma (for specialized target groups only)
Stivarga ® (regorafenib) is the first and only systemic treatment to demonstrate significant improvement in overall survival in second-line hepatocellular carcinoma (HCC) patients and the first treatment advance in nearly a decade / Pivotal trial RESORCE defines a new treatment plan in hepatocellular carcin oma (HCC) with Stivarga directly after Nexavar® (sorafenib) (Source: Bayer Company News)
Source: Bayer Company News - June 26, 2017 Category: Pharmaceuticals Source Type: news

Bayer Receives Positive CHMP Opinion for regorafenib for the Second-Line Systemic Treatment of Liver Cancer (for specialized target groups only)
Positive opinion based on data from the Phase III RESORCE study, in which regorafenib demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar ® (sorafenib) / Approval could provide first treatment advance in nearly a decade / Final decision from the European Commission anticipated within the next two months (Source: Bayer Company News)
Source: Bayer Company News - June 23, 2017 Category: Pharmaceuticals Source Type: news

Lenvatinib for Unresectable Liver Cancer Noninferior to Sorafenib
Lenvatinib demonstrated noninferiority to sorafenib with regard to overall survival in patients with previously untreated, unresectable hepatocellular carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gastrointestinal Cancer Liver, Gallbladder, and Biliary Tract Cancers News Source Type: news

BTG touts digital patient engagement platform with TheraSphere treatment
BTG (LON:BTG) touted data last week from a pilot study of its digital patient engagement platform IO Loop in patients with primary hepatocellular carcinoma undergoing treatment with the company’s TheraSphere transarterial radioembolization therapy. The study found that patients experienced sustained quality of life up to 3 months after treatment. The company called the study of its novel data collection tool the “the first-of-its-kind” in interventional oncology. Get the full story at our sister site, Drug Delivery Business News. The post BTG touts digital patient engagement platform with TheraSphere trea...
Source: Mass Device - June 12, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Patient Monitoring Vascular BTG Source Type: news

How bile duct cancer develops and how it can be prevented
(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) What promotes the development of bile duct cancer in the liver? Are these factors different from those that are responsible for the much more common hepatocellular carcinomas? Scientists from the Heidelberg and Munich have been the first to uncover the molecular causes that selectively lead to the development of bile duct cancer in mice. The researchers also discovered that antioxidants or an inhibitor of a specific key enzyme can be used to stop this cancer-promoting process. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 12, 2017 Category: Cancer & Oncology Source Type: news

New Risk Model May Help Select Patients With HCC for Liver Transplantation New Risk Model May Help Select Patients With HCC for Liver Transplantation
A new risk score to predict five-year survival after liver transplant of patients with hepatocellular carcinoma (HCC) displayed better prognostic ability than other models when tested in a database of nearly 14,000 patients.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Pembrolizumab Plus Pazopanib Is Not Safe for Patients with RCC
Liver toxicity precludes development of pembrolizumab plus pazopanib immunotherapy for patients with advanced renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Renal Cell Carcinoma News Source Type: news

10 Facts Women Should Know About Endometrial Cancer
The most common cancer of the reproductive organs in American women is endometrial cancer. The American Cancer Society estimates that for the year 2017, around 61,380 new cases of cancer of the body of the uterus will be diagnosed and about 10,920 women will die from cancers of the uterine body. These figures include both endometrial cancers and uterine sarcomas. Since endometrial cancer is a fairly common cancer in women, the more women know the facts about this disease, the greater their chance of knowing what symptoms to be aware of in order to have it diagnosed as early as possible, improving the likelihood of surviva...
Source: Healthy Living - The Huffington Post - June 5, 2017 Category: Consumer Health News Source Type: news

Sirtex SIR-spheres fail to meet primary endpoint in head-to-head trial
Sirtex Medical (ASX:SRX) shares are down slightly today after its radioactive microspheres failed to meet the primary endpoint in a liver cancer trial. The company’s SIR-Spheres Y-90 resin microspheres did not improve survival in patients with advanced hepatocellular carcinoma compared to a group treated with the current standard of care, sorafenib. Get the full story at our sister site, Drug Delivery Business News. The post Sirtex SIR-spheres fail to meet primary endpoint in head-to-head trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 5, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Wall Street Beat Sirtex Medical Source Type: news

Methanol from African Plants Kills Mesothelioma Cells
This study provides evidences of the cytotoxicity of the tested plant extract and highlights the good activity of Elephantopus mollis and Kalanchoe crenata,” Kuete wrote. “They deserve more exploration to develop novel cytotoxic drugs.” The post Methanol from African Plants Kills Mesothelioma Cells appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - June 2, 2017 Category: Environmental Health Authors: Matt Mauney Tags: African medicinal plants African whitewood apoptosis mesothelioma BMC Complementary and Alternative Medicine breast cancer Cameroon cancer chemotherapy colon cancer cytotoxicity against mesothelioma cells doxorubicin Dr. Victor Kuete Source Type: news

FDA approves new drug to treat type of liver cancer
The U.S. Food& Drug Administration Thursday approved a new drug to treat the most common form of liver cancer, hepatocellular carcinoma. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 4, 2017 Category: Consumer Health News Source Type: news

FDA-approved drug for most common form of liver cancer was tested in clinical trials led by UCLA
A drug to treat the most common form of liver cancer was approved by the FDA on April 27. UCLA ’s Dr. Richard Finn led the clinical studies that led to the approval of the medication, regorafenib, and UCLA was the leader of the U.S. arm of the research, which involved 21 other sites in the U.S., Europe and Asia.The drug is used to treat hepatocellular carcinoma, which accounts for three-quarters of the cases of liver cancer in the U.S. and is the second leading cause of cancer-related deaths worldwide. In trials, regorafenib significantly improved survival rates after standard treatments failed.“When liver canc...
Source: UCLA Newsroom: Health Sciences - May 4, 2017 Category: Universities & Medical Training Source Type: news

Nivolumab Improves Sorafenib-Treated Liver Cancer Nivolumab Improves Sorafenib-Treated Liver Cancer
Nivolumab immunotherapy could provide a durable response, and increase survival, for patients with advanced hepatocellular carcinoma who do not respond completely to sorafenib, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 28, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Bayer Receives FDA Approval for Stivarga ® (regorafenib) for the Second-Line Systemic Treatment of Liver Cancer (for specialized target groups only)
Stivarga is the first and only systemic treatment to demonstrate significant improvement in overall survival in second-line hepatocellular carcinoma (HCC) patients previously treated with Nexavar ® (sorafenib) / First new treatment for HCC in a decade / Pivotal Phase III RESORCE trial defines a new treatment plan in HCC which involves use of Stivarga directly after progression on Nexavar (Source: Bayer Company News)
Source: Bayer Company News - April 28, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Regorafenib for Liver Cancer
The FDA has approved regorafenib (Stivarga) for the second-line treatment of hepatocellular carcinoma (HCC) for patients who have previously received sorafenib. (Source: CancerNetwork)
Source: CancerNetwork - April 28, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Gastrointestinal Cancer Liver, Gallbladder, and Biliary Tract Cancers News Source Type: news

First New Drug for Liver Cancer in a Decade: Regorafenib First New Drug for Liver Cancer in a Decade: Regorafenib
The FDA has approved an expanded indication for regorafenib to include hepatocellular carcinoma, making it the first drug to be approved for this cancer in a decade.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 28, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Regorafenib Approved for Hepatocellular Carcinoma
It is the first approved treatment for HCC in almost a decade (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 28, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Institutional, Source Type: news

FDA Expands Approved Use of Stivarga (regorafenib) to Treat Hepatocellular Carcinoma
April 27, 2017 -- The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 27, 2017 Category: Drugs & Pharmacology Source Type: news

FDA expands approved use of Stivarga to treat liver cancer
The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib. This is the first FDA-approved treatment for a liver cancer in almost a decade. (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 27, 2017 Category: American Health Source Type: news

New studies refocus attention on the genotoxicity of AAV vectors in gene therapy
(Mary Ann Liebert, Inc./Genetic Engineering News) A growing number of preclinical studies in mice suggests that therapeutic gene delivery using recombinant adeno-associated viral vectors (rAAVs) can cause insertional mutagenesis and increase the risk of hepatocellular carcinoma. Despite the apparent safety of rAAV-mediated gene therapy in human clinical applications, the data emerging from some mouse studies emphasize the need to carefully reconsider the potential risk of genotoxicity, according to the authors of a provocative article published in Human Gene Therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 26, 2017 Category: Global & Universal Source Type: news

SillaJen and Transgene commence enrolment in Europe for Phase III trial of Pexa-Vec
South Korean-based biotherapeutics firm SillaJen and French biotechnology firm Transgene have commenced patient enrolment in Europe for the ongoing Phase III PHOCUS clinical trial of Pexa-Vec to treat advanced liver cancer or hepatocellular carcinoma … (Source: Drug Development Technology)
Source: Drug Development Technology - April 25, 2017 Category: Pharmaceuticals Source Type: news

Medical News Today: Advanced liver cancer: Selective internal radiation therapy safer than sorafenib
A phase III trial of selective internal radiation therapy for hepatocellular carcinoma has found the treatment is safer and just as effective as sorafenib. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 25, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Tiziana to initiate Phase II trial of milciclib in Israel to treat hepatocellular carcinoma
UK-based biotechnology firm Tiziana Life Sciences has received approval for the initiation of its Phase II clinical trial of milciclib in Israel to treat refractory hepatocellular carcinoma (HCC). (Source: Drug Development Technology)
Source: Drug Development Technology - April 24, 2017 Category: Pharmaceuticals Source Type: news

Study: Sirtex ’ s microspheres improve quality of life, but don ’ t extend survival
Sirtex Medical (ASX:SRX) said today that it’s yttrium-90 resin microspheres did not extend survival significantly compared to Bayer’s sorafenib in a study of patients with hepatocellular carcinoma. Although the 459-patient trial did not meet its primary endpoint, the company reported that patients treated with its microspheres experienced less than half the number of severe, treatment-related adverse effects than those who received the standard, twice-daily systemic treatment with sorafenib. “Neither sorafenib nor SIR-Spheres Y-90 resin microspheres produced a statistically significant difference in overa...
Source: Mass Device - April 24, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Wall Street Beat Sirtex Medical Source Type: news

SIR-Spheres(R) Y-90 Resin Microspheres Substantially Improves Quality of Survival in Primary Liver Cancer, New Study Against Standard Treatment Shows
459-patient SARAH Study shows that local treatments of advanced or inoperable Hepatocellular Cancer (HCC) with SIR-Spheres Y-90 resin microspheres did not lead to a planned superiority difference in overall survival compared to daily standard-of-care syste... Devices, Oncology Sirtex Medical Limited, SIR-Spheres, microspheres, Hepatocellular Carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 24, 2017 Category: Pharmaceuticals Source Type: news

Nivolumab Yields 12-Month Survival of Nearly 60% in Advanced HCC
Interim data from CheckMate 040 showed that nivolumab produces durable responses with promising long-term survival rates in patients with advanced, unresectable hepatocellular carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - April 21, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Gastrointestinal Cancer Liver, Gallbladder, and Biliary Tract Cancers News Source Type: news

Elevated Liver Cancer Risk for Older Hep B-Cleared Patients Elevated Liver Cancer Risk for Older Hep B-Cleared Patients
Even after a functional cure for hepatitis B is achieved, the risk for hepatocellular carcinoma persists in older patients, new research warns.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 21, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Spermidine-rich foods may prevent liver cancer, extend lifespan
Spermidine —a compound found in foods like aged cheese, mushrooms, soy products, legumes, corn and whole grains—seems to prevent (at least in animal models) liver fibrosis and hepatocellular carcinoma, which is the most common type of liver cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 21, 2017 Category: Science Source Type: news

First European patients treated with BTG ’ s drug-eluting bead
BTG (LON:BTG) said today that the 1st batch of patients in the European Union were treated with its DC Bead Lumi radiopaque drug-eluting bead. Two patients were treated for hepatocellular carcinoma and 1 patient was treated for malignant colorectal cancer metastasized to the liver. The bead, which is the 1st commercially available radiopaque drug-eluting bead in the EU, uses doxorubicin or irinotecan to locally treat tumors. Get the full story at our sister site, Drug Delivery Business News. The post First European patients treated with BTG’s drug-eluting bead appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 20, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Oncology Pharmaceuticals Wall Street Beat BTG Source Type: news

Liver progenitor cells are involved in the development of hepatic tumors
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) The malignant transformation of hepatocytes is the origin of most hepatocellular carcinomas, an aggressive type of liver cancer with high mortality rates. But these cells do not act alone. Research conducted by scientists at the Spanish National Cancer Research Centre (CNIO) reveals how hepatocytes 'recruit' and 'instruct' liver progenitor cells to contribute to the hepatic lesions. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 18, 2017 Category: Cancer & Oncology Source Type: news

Hep C Treatment Triumph Drives Broader Focus for ILC 2017 Hep C Treatment Triumph Drives Broader Focus for ILC 2017
Clinical trial results for biliary cirrhosis and hepatocellular carcinoma are highly anticipated at the upcoming International Liver Congress (ILC).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 11, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Metabolic mechanism identified for R-LA induced cell death in liver cancer cells
(Mary Ann Liebert, Inc./Genetic Engineering News) A new study that measured metabolite levels over time in starved rat liver cancer cells showed that treatment with a form of alpha-lipoic acid (LA) inhibited glucose uptake and glycolysis, and led to decreased cellular glucose production from non-carbohydrate sources, which may help explain how the naturally occurring R enantiomeric form of LA (R-LA) promotes the death of hepatoma cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 11, 2017 Category: Global & Universal Source Type: news